Clinical Trial

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

Study acronym: EpiDRIVE
Recruiting
View on ClinicalTrials.gov →
Summary
The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy. By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predictive biomarker panel capable of differentiating responders from non-responders to targeted therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-03.
Trial Details
NCT Number NCT07224841
Lead Sponsor City of Hope Medical Center
Conditions CRC (Colorectal Cancer)
Enrollment 500 participants
Start Date 2024-06-21
Primary Completion 2028-06-18 (estimated)
Study Completion 2028-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-07